Group 1 - The Hang Seng Index and the Hang Seng Tech Index both turned negative, with the Hang Seng Index declining by 0.2% [1] - Alibaba Health and JD Health both experienced declines of over 4% [1]

Core Insights - The first and only approved stem cell drug in China, Aimi Maitosai Injection, has made significant progress with its first prescription issued in Beijing, marking the start of its commercial clinical application [1] - The drug, developed by domestic company Platinum Bio, is aimed at treating acute graft-versus-host disease (aGVHD) in patients over 14 years old who have failed hormone therapy [1] - The cost of Aimi Maitosai Injection is approximately 20,000 RMB per bag, significantly lower than similar products in the US, which are priced at 190,000 USD per bag, thus reducing the financial burden on patients [1] Product Development and Market Expansion - Aimi Maitosai Injection has transitioned the treatment of aGVHD from a single-target approach to a multi-target and multi-pathway treatment strategy [1] - The drug's service has achieved nationwide coverage in China, facilitated by strategic partner Alibaba Health, with appointment services available in over 20 provinces including Beijing, Shanghai, and Guangdong [1] - Ongoing research is being conducted to expand the drug's indications to include diabetic nephropathy, acute kidney injury, and vascular aging, potentially broadening its application in various disease areas [1]

Core Viewpoint - Alibaba Health (00241) announced the grant of a total of 949,000 restricted stock units to 17 grantees under the 2024 share incentive plan, pending acceptance for it to take effect [1] Summary by Category - **Company Announcement** - The company will grant 949,000 restricted stock units to 17 individuals as part of its incentive plan [1]

智通财经APP讯，阿里健康(00241)发布公告，于2025年9月15日，公司根据2024年股份奖励计划的条款 向17名承授人授出合共94.9万个受限制股份单位，惟须待接纳后方可作实。 ...

Core Viewpoint - Alibaba Health (00241.HK) has granted a total of 950,000 restricted share units to 17 recipients under the 2024 Share Award Plan, pending acceptance, aimed at promoting the company's development and expansion [1] Group 1: Purpose of Granting Restricted Share Units - The purpose of granting restricted share units includes providing opportunities for individuals with skills and experience to acquire equity in the company, thereby attracting them to facilitate further development and expansion of the group [1] - It also serves to recognize the contributions of existing employees to the success and development of the group [1] - Additionally, the grant aims to fully incentivize and motivate employees to remain with the group, promoting future growth and expansion [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 於2025年9月15日，本公司根據2024年股份獎勵計劃之條款向17名承授人授出合 共949,000個受限制股份單位，惟須待接納後方可作實。 本公告乃根據上市規則第17.06A、17.06B及17.06C條作出。 受限制股份單位 本公告僅供參考之用，並不構成收購、購買或認購阿里健康信息技術有限公司股份 的邀請或要約。 ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） （股份代號：00241） 授出受限制股份單位 授出受限制股份單位 於2025年9月15日，本公司根據2024年股份獎勵計劃之條款向17名承授人授出合共 949,000個受限制股份單位，惟須待接納後方可作實。授出受限制股份單位之詳情 如下： 授出日期 ： 2025年9月15日 承授人 ： 向承授人授出合共949,000個受限制股份單位，彼等為本 ...

9月9日，港股互联网医疗概念板块一骑绝尘，成为当日市场的领涨先锋。 板块内，个股涨势喜人。截至发稿前，叮当健康（09886.HK）涨9.76%，阿里健康（00241.HK）大涨9.40%，京东健康（06618.HK）、平安好医生 （01833.HK）也都加入这股上涨浪潮，涨幅分别为6.58%、3.39%。 | 序号 | 財華社 FINET 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 √ | | --- | --- | --- | --- | --- | --- | | 1 | 09886 | 叮当健康 | (0) 0.900 | +0.080 | 9.76% | | 2 | 00241 | 阿里健康 | 7.100 | +0.610 | 9.40% | | 3 | 06618 | 京东健康 | 1 67.200 | +4.150 | 6.58% | | 4 | 01833 | 平安好医生 | 11 21.940 | +0.720 | 3.39% | | 5 | 06060 | 众安在线 | 18.450 | +0.040 | 0.22% | | 6 | 02159 | 麦迪 康 | 1.490 | 0 ...

Group 1 - Alibaba Health (00241) shares increased by 10%, reaching a high of 7.18 HKD, the highest since January 2023, with a trading volume of 2.036 billion HKD [1] - HSBC Global Research anticipates that health products will continue to be the fastest-growing category for Alibaba Health, supported by its strong platform ecosystem [1] - The focus on first-party sales (1P) profitability may limit sales growth for pharmaceuticals, but the shift of offline traffic to online due to tightened social insurance claims is expected to benefit Alibaba Health from strong demand for innovative drugs [1] Group 2 - The sales momentum of innovative drugs exceeding expectations may provide upward potential for revenue and net profit forecasts [1] - The National Medical Products Administration is drafting a compliance guideline for online retail of prescription drugs to enhance compliance awareness and capabilities among stakeholders [1] - The guideline emphasizes that companies must fulfill their responsibilities for drug safety and continuously improve their quality management systems and compliance management [1]

Group 1 - Alibaba Health (00241) shares increased by 10%, reaching a high of 7.18 HKD, the highest since January 2023, with a trading volume of 2.036 billion HKD [1] - HSBC Global Research anticipates that health products will continue to be the fastest-growing category for Alibaba Health, supported by its robust platform ecosystem [1] - The focus on first-party sales (1P) profitability may limit sales growth in pharmaceuticals, but the shift of offline traffic to online due to tighter social insurance claims is expected to benefit Alibaba Health from strong demand for innovative drugs [1] Group 2 - The unexpected sales momentum of innovative drugs may provide upward potential for revenue and net profit forecasts for Alibaba Health [1] - The National Medical Products Administration is drafting a compliance guideline for online prescription drug sales to enhance compliance awareness and capabilities among stakeholders [1] - The guideline emphasizes that companies must fulfill their responsibilities for drug safety and continuously improve their quality management systems and compliance management [1]

Group 1 - The Hang Seng Index rose by 0.80%, the Hang Seng Tech Index increased by 1.03%, and the Hang Seng China Enterprises Index strengthened by 0.90% during the midday session, with a market turnover of HKD 159.68 billion [1] - The southbound capital has become a stabilizer for the Hong Kong stock market, with a cumulative net inflow exceeding HKD 100 billion since the beginning of the year, particularly benefiting sectors such as commerce and retail, telecommunications, electronics, media, and computer technology [1] - The current interest rate cut cycle by the Federal Reserve is attracting more global allocation funds to the Hong Kong stock market, with historical data indicating that the Hong Kong stock market performs well during preventive interest rate cut cycles [1] Group 2 - The Hong Kong Stock Connect Technology ETF (159101) closely tracks the CSI Hong Kong Stock Connect Technology Index, covering major tech leaders such as Xiaomi, Tencent, Alibaba, Meituan, BYD, SMIC, and BeiGene, with the top five constituents accounting for 57% of the weight [2] - The ETF supports T+0 trading and does not occupy QDII quotas, allowing investors to flexibly apply allocation strategies based on their needs, such as using it as a core holding for growth assets or capturing market trends with high elasticity [2] - The ETF provides a one-stop solution for "software + hardware + new consumption + innovative drugs + new energy vehicles," making it suitable for long-term investors, trend investors, and those looking to smooth risks through dollar-cost averaging [2]